MedTrace Logo

Treatment Response of High-dose and Standard-dose Rabeprazole for Extra-esophageal Reflux.

NCT04001400 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2019-06-28

No results posted yet for this study

Summary

This is a single-center, randomized, open-label clinical study to assess the treatment response of high-dose rabeprazole compared with standard-dose rabeprazole in patients with extra-esophageal manifestations of gastroesophageal reflux disease.

Conditions

  • Esophageal Disease

Interventions

DRUG

Rabeprazole 20mg bid

Rabeprazole 20mg tablet b.i.d.

DRUG

Rabeprazole 20mg qd

Rabeprazole 20mg tablet q.d.

Sponsors & Collaborators

  • IlDong Pharmaceutical Co Ltd

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Dong Ho Lee, MD, PhD · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-10
Primary Completion
2014-05-21
Completion
2014-05-21

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04001400 on ClinicalTrials.gov